Overview

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Status:
Completed
Trial end date:
2020-06-19
Target enrollment:
Participant gender:
Summary
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Novartis Pharmaceuticals
Treatments:
Bevacizumab
Lapatinib